Skip to content

Orion Group Annual Report 2010 published

ORION CORPORATION STOCK EXCHANGE RELEASE 9 March 2011 AT 13.30 EET Orion Group's Annual Report 2010, including Financial Statements, is now available in Finnish and English on company's website at This year, Orion will publish its annual report for the first time only as an online report. Printed copies of Financial Statement documents will be mailed upon request. Financial Statement documents can be ordered on company's website at Orion's Corporate Governance Statement for year 2010, adopted by the Board of Directors, is published as a separate report at Orion Corporation
Olli Huotari
SVP, Corporate Functions  
Terhi Ormio
VP, Communications

Attached PDF versions:

Orion Annual Report 2010.pdf
Orion Financial Statement documents 2010.pdf

Orion Corporation
Orionintie 1A, 02200 Espoo



Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.


The Group's net sales in 2010 amounted to approximately EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.